Biotech Startups

Basilard BioTech develops Celletto, a nanomechanical (mechanoporation) gene delivery platform that inserts genes directly into the nucleus of cells without viral vectors, aimed at cell and gene therapy (CGT) developers and manufacturers. The technology targets the gene-delivery bottleneck in engineering cell-based therapies, offering an alternative to viral, chemical, and physical delivery methods.

4 investors

Becoming.bio develops robotic systems that sustain mammalian development outside the body, combining closed-loop hardware for metabolic regulation with AI models that predict how organisms develop and respond to intervention. The company works at the intersection of biology, robotics, and machine learning to study developmental processes and disease.

4 investors

Biocartis develops Idylla, a fully automated real-time PCR molecular testing system that delivers biomarker results in about three hours for oncology applications. The company targets clinical labs, oncologists, and pathologists, and runs partnership programs with pharmaceutical and diagnostic companies.

4 investors

Bioflyte provides chemical and biological threat detection solutions for critical infrastructure and business operations, enabling organizations to monitor, identify and respond to bio/chem threats. The company serves government agencies, critical infrastructure operators, and other organizations responsible for security and safety.

4 investors

Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options. Its commercialized products include migraine therapies, and it advances a portfolio of early- to late-stage drug development programs.

4 investors

Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.

4 investors

Biomason uses biotechnology to grow biocement, producing concrete and tile products by using bacteria to bind natural materials as an alternative to Portland cement, aimed at concrete producers and the construction industry. Founded in North Carolina with manufacturing and market development in Denmark, the company sells tile products installed in the US and Europe and is developing pavers and walls, with a focus on the European market.

4 investors

BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security. It targets field-proven products serving homeland security, critical infrastructure, border, transportation, and public safety needs within a Detection, Analysis, and Response operational chain.

4 investors

BioNTech is a biotechnology company developing immunotherapies that use the body's immune system, combining multiple therapeutic modalities and biological targets to treat cancer, infectious diseases, and other serious conditions. It operates globally in the pharmaceutical and biotech industry.

4 investors

Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease. Its pipeline includes TL1A, TL1A*IL-23p19 bispecific, and IL-25 antibodies with half-life extension technology.

4 investors

BioRender is a software tool that enables scientists to create and share professional scientific illustrations and figures. The platform serves researchers and scientists across life sciences disciplines globally.

4 investors

bitBiome provides contract analysis and collaborative research using single-cell genome sequencing technology for microbial samples. The company serves clients in biotech and related manufacturing sectors in Japan and the U.S.

4 investors

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes. It markets approved therapies internationally and runs patient access programs across multiple countries.

4 investors

BLUU develops marine cell-based ingredients derived from cultured fish cells for personal care, health, and food applications. The company uses proprietary bioprocessing workflows grounded in peer-reviewed research to produce ethically sourced, traceable compounds that replicate results unattainable through land-based agriculture.

4 investors

BluumBio identifies and deploys naturally occurring enzymes from fungi, trees, and bacteria to remove industrial pollutants from soil, air, and water. The company serves environmental remediation projects requiring rapid decontamination of petroleum, pesticides, plastics, and other synthetic chemicals.

4 investors

Boston Bioprocess provides fermentation and bioprocess development services—including scale-up across 1.5L to 1,500L vessels, downstream process development, regulatory guidance, and tech transfer to CMOs—for companies bringing biomanufactured products to production. It also offers software and AI-driven process intelligence for lab execution, batch record management, scheduling, and results analysis.

4 investors

BRAINBox Solutions develops a multi-modality diagnostic approach for mild traumatic brain injury (mTBI), combining blood biomarker panels with tablet-based neurocognitive testing to produce an objective injury score and a prognosis of post-injury symptoms. The tools are aimed at clinicians for diagnosing concussion and predicting patient outcomes.

4 investors

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.

4 investors

Cadenza Bio develops small-molecule drugs for oral administration to treat demyelinating and inflammatory diseases. The company focuses on halting disease progression and promoting tissue repair in patients with debilitating conditions.

4 investors

CamGene Therapeutics develops RNA-based medicines, including mRNA, siRNA, and antisense oligonucleotides delivered via lipid nanoparticles, to treat the underlying cellular dysfunction that causes hearing loss. The company aims to modulate protein expression for regeneration and protection of cells in the cochlea as an accessible mass-market therapeutic.

4 investors

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

4 investors

Caravel engineers proteins into scalable industrial "protein machines" for applications including critical minerals recovery, carbon capture, and industrial processes. The company develops a protein engineering platform aimed at reducing the time and cost of scaling proteins for industrial use.

4 investors

Cardiac Insight develops handheld and wearable ECG devices for cardiac diagnostics, including the Cardea 20/20 for athlete heart screening and the Cardea SOLO for 7-day ambulatory monitoring. The company serves healthcare providers and patients seeking reliable electrocardiogram analysis and cardiac evaluation.

4 investors

Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies aimed at treating autoimmune diseases. It focuses on immunology and applies an mRNA platform to broaden the use of cell therapy for patients.

4 investors